Efficacy and Safety of Dolutegravir With Emtricitabine and Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate, and Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate HIV Antiretroviral Therapy Regimens Started in Pregnancy oIMPAACT 2010/VESTEDTHORN: A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial

被引：0
|
作者：
Aquino, Marcella
机构：
来源：
PEDIATRICS | 2021年 / 148卷
关键词：
D O I：
10.1542/peds.2021-053843YYYY
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [41] Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial
    Thurman, Andrea R.
    Schwartz, Jill L.
    Cottrell, Mackenzie L.
    Brache, Vivian
    Chen, Beatrice A.
    Cochon, Leila
    Ju, Susan
    McGowan, Ian
    Rooney, James F.
    McCallister, Scott
    Doncel, Gustavo F.
    ECLINICALMEDICINE, 2021, 36
  • [42] Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
    De Castro, Nathalie
    Brun, Alexandre
    Sellier, Pierre
    Hamet, Gwenn
    Mechai, Frederic
    Garrait, Valerie
    Chabrol, Amelie
    Bouldouyre, Marie-Anne
    Froguel, Eric
    Troisvallets, Didier
    Caraux-Paz, Pauline
    Delaugerre, Constance
    Rozenbaum, Willy
    Molina, Jean-Michel
    AIDS RESEARCH AND THERAPY, 2023, 20 (01)
  • [43] Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir plus emtricitabine/tenofovir Disoproxil Fumarate (DTG plus F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE)
    Avihingsanon, A.
    Lu, H.
    Leong, C. L.
    Hung, C. -C.
    Koenig, E.
    Kiertiburanakul, S.
    Lee, M. -P.
    Supparatpinyo, K.
    Zhang, F.
    Rahman, S.
    Brogan, M. D'Antoni
    Wang, H.
    Hindman, J.
    Martin, H.
    Baeten, J.
    Li, T.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 226 - 227
  • [44] Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
    Nathalie De Castro
    Alexandre Brun
    Pierre Sellier
    Gwenn Hamet
    Frédéric Mechaï
    Valérie Garrait
    Amélie Chabrol
    Marie-Anne Bouldouyre
    Eric Froguel
    Didier Troisvallets
    Pauline Caraux-Paz
    Constance Delaugerre
    Willy Rozenbaum
    Jean-Michel Molina
    AIDS Research and Therapy, 20
  • [45] The 5-year safety and efficacy of the once-daily antiretroviral-naive patient regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
    Johnson, M.
    Lazzarin, A.
    Ribera, E.
    Weitner, L.
    Chen, S. S.
    HIV MEDICINE, 2011, 12 : 76 - 76
  • [46] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
    DeJesus, Edwin
    Rockstroh, Juergen K.
    Henry, Keith
    Molina, Jean-Michel
    Gathe, Joseph
    Ramanathan, Srinivasan
    Wei, Xuelian
    Yale, Kitty
    Szwarcberg, Javier
    White, Kirsten
    Cheng, Andrew K.
    Kearney, Brian P.
    LANCET, 2012, 379 (9835): : 2429 - 2438
  • [47] Long-term efficacy and safety of a maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate
    Borjabad, Beatriz
    Inciarte, Alexy
    Chivite, Ivan
    Gonzalez-Cordon, Anna
    Mosquera, Maria Del Mar
    Torres, Berta
    De la Mora, Lorena
    Martinez-Rebollar, Maria
    Laguno, Montserrat
    Foncillas, Alberto
    Ambrosioni, Juan
    Mallolas, Josep
    Rovira, Cristina
    Hurtado, Carmen
    Sempere, Abiu
    Calvo, Julia
    Berrocal, Leire
    Miro, Jose M.
    Alcami, Jose
    Blanco-Arevalo, Jose Luis
    Sanchez-Palomino, Sonsoles
    De lazzari, Elisa
    Martinez, Esteban
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 135 - 136
  • [48] A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals
    Fisher, Martin
    Moyle, Graeme J.
    Shahmanesh, Mohsen
    Orkin, Chloe
    Kingston, Margaret
    Wilkins, Edmund
    Ewan, Jacqueline
    Liu, Hui
    Ebrahimi, Ramin
    Reilly, Geraldine
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (05) : 562 - 568
  • [49] WEEK 48 RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) VS DOLUTEGRAVIR plus EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (DTG plus F/TDF) IN ART-NAIVE, HIV/HBV-COINFECTED ADULTS (ALLIANCE)
    Avihingsanon, Anchalee
    Lu, Hongzhou
    Leong, Chee Loon
    Hung, Chien-Ching
    Koenig, Ellen
    Kiertiburanakul, Sasisopin
    Lee, Man-Po
    Supparatpinyo, Khuanchai
    Rahman, Sophia
    Brogan, Michelle D'Antoni
    Wang, Hongyuan
    Hindman, Jason
    Martin, Hal
    Mehta, Swarup S.
    Baeten, Jared
    Zhang, Fujie
    GASTROENTEROLOGY, 2023, 164 (06) : S1241 - S1241
  • [50] Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients
    Huang, Yu-Shan
    Cheng, Chien-Yu
    Sun, Hsin-Yun
    Cheng, Shu-Hsing
    Lu, Po-Liang
    Lee, Chen-Hsiang
    Lee, Yuan-Ti
    Tsai, Hung-Chin
    Yang, Chia-Jui
    Liu, Chun-Eng
    Liou, Bo-Huang
    Lin, Shih-Ping
    Huang, Sung-Hsi
    Ho, Mao-Wang
    Tang, Hung-Jen
    Hung, Chien-Ching
    MICROBIOLOGY SPECTRUM, 2023, 11 (03):
12345